$SI

Gilde Healthcare Holding B.V. sold $213K of SI (indirect holdings)

Gilde Healthcare Holding B.V. sold 9,433 indirectly-held shares of SHOULDER INNOVATIONS, INC. (SI) at an average of $22.63 ($22.60–$22.64, $0.21M total) across 2 trades over 2026-08-05 to 2026-08-06.

Original reporting
SEC EDGAR · Gilde Healthcare Holding B.V.
Published Aug 7, 2026, 8:12 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 9:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SI
Neutral
medium confidence
Mentioned
$SI
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SINeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale by a 10% owner at a specific price range, with no 10b5-1 plan noted. This can slightly influence sentiment but does not change fundamentals based on the provided text.

02

Market read

A disclosed 10% owner sale at roughly $22.63 per share may create minor near-term sentiment noise, but there is no accompanying fundamental update.

03

What to watch

Because the transaction is indirect and the filing does not state the reason for sale, traders may overinterpret it without corroborating signals (e.g., follow-on sales, changes in guidance, or material company events).

Relevance 4/10Novelty 3/10Timing: Form 4 filed Aug 7, covering sales on Aug 5-6.

Background

The article is an SEC Form 4 insider transaction disclosure for Shoulder Innovations, Inc. (SI).

Company-level read

Ticker impact

$SINeutralMedium confidence
Context

Gilde Healthcare Holding B.V., a 10% owner, sold 9,433 SI shares in open-market trades at about $22.63, per Form 4 filed Aug 7.

Expected impact

Low likelihood of a sustained price move; any impact is likely limited to short-term sentiment around the sale.

Evidence & confidence

The filing discloses transaction size and price range, but provides no new operating, regulatory, or financial information. Insider sales are common and often not predictive without additional context.

Market effects

No sector read-through is provided; this is a single-issuer insider transaction.

None indicated.

None indicated.

Counterpoint

The sale could be routine liquidity management by a large holder, especially since the filing does not indicate any adverse company-specific event.

Key entities

  • Shoulder Innovations, Inc.

    Subject of the Form 4 insider transaction disclosure (SI).

  • Gilde Healthcare Holding B.V.

    Reporter of the indirect open-market sale of SI shares.

Related articles

$SIMed

Siemens to acquire EDA software firm Precision Innovations

Siemens said it signed an agreement to acquire privately held US EDA software firm Precision Innovations. Siemens said the deal will add AI-powered chip planning and early design exploration using the OpenROAD framework to help semiconductor teams optimize power, performance and area, reduce iterations, and speed SoC feasibility analysis and time to market.

$SIMedAI 8/10

SHOULDER INNOVATIONS, INC. (SI): Results of Operations and Financial Condition

SHOULDER INNOVATIONS, INC. (SI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-991earningsreleaseq22026.htm EX-99.1 Document Exhibit 99.1 Shoulder Innovations Reports Second Quarter 2026 Financial Results and Raises Full Year Outlook Generates First Half 2026 Revenue Growth of 60% Grand Rapids, MI – August 6, 2026 – Shoulder Innovations, Inc. (

$SIMed

Siemens to acquire chip design firm Precision Innovations

Siemens said it agreed to acquire privately held Precision Innovations Inc., an electronic design automation firm. Siemens will add Precision’s AI-powered chip planning tools to its EDA portfolio to help semiconductor teams evaluate design tradeoffs earlier in system-on-a-chip development, aiming to improve power, performance and area outcomes and speed time to production.

$QTTBMedAI 8/10

Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus

Biotech gainers highlighted Q32 Bio (QTTB), up 90.7% to $21.38 after positive Phase 2 SIGNAL-AA results for bempikibart in alopecia areata, and it launched a $200M underwritten stock offering. Agenus (AGEN) rose 82.7% to $6.12 on a planned ~$85M private placement for BOT+BAL Phase 3 ROBBIN1. Other movers: ACTU, GALT, AMWL, SI.